These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 31281432)

  • 1. Effect of FOLFOX on minimal residual disease in Stage III colon cancer and risk of relapse.
    Murray NP; Aedo S; Villalon R; López MA; Minzer S; Muñoz L; Orrego S; Contreras L; Arzeno L; Guzman E
    Ecancermedicalscience; 2019; 13():935. PubMed ID: 31281432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subtypes of minimal residual disease and outcome for stage II colon cancer treated by surgery alone.
    Murray NP; Aedo S; Villalon R; Albarran V; Orrego S; Guzman E
    Ecancermedicalscience; 2020; 14():1119. PubMed ID: 33209110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Dysfunction as Measured by the Systemic Immune-Inflammation Index is Associated with the Sub-Type of Minimal Residual Disease and Outcome in Stage II Colon Cancer Treated with Surgery alone.
    Murray NP; Villalon R; Orrego S; Guzman E
    Asian Pac J Cancer Prev; 2021 Aug; 22(8):2391-2397. PubMed ID: 34452551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subtypes of minimal residual disease, association with Gleason score, risk and time to biochemical failure in pT2 prostate cancer treated with radical prostatectomy.
    Murray NP; Aedo S; Fuentealba C; Reyes E; Salazar A; Lopez MA; Minzer S; Orrego S; Guzman E
    Ecancermedicalscience; 2019; 13():934. PubMed ID: 31281431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The CAPRA score versus sub-types of minimal residual disease to predict biochemical failure after external beam radiotherapy.
    Murray NP; Aedo S; Fuentealba C; Reyes E; Salazar A; Guzman E; Orrego S
    Ecancermedicalscience; 2020; 14():1042. PubMed ID: 32565895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement in immune dysfunction after FOLFOX chemotherapy for Stage III colon cancer is associated with improved minimal residual disease prognostic subtype and outcome.
    Murray NP; Villalon R; Hartmann D; Rodriguez MP; Aedo S
    Colorectal Dis; 2021 Nov; 23(11):2879-2893. PubMed ID: 34473913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The association of the neutrophil-lymphocyte ratio with the presence of minimal residual disease and outcome in patients with Stage II colon cancer treated with surgery alone.
    Murray NP; Villalon R; Orrego S; Guzman E
    Colorectal Dis; 2021 Apr; 23(4):805-813. PubMed ID: 33169474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement in the Neutrophil-Lymphocyte Ratio after Combined Fluorouracil, Leucovorina and Oxaliplatino based (FOLFOX) Chemotherapy for Stage III Colon Cancer is Associated with Improved Minimal Residual Disease and Outcome.
    Murray NP; Villalon R; Hartmann D; Rodriguez PM; Aedo S
    Asian Pac J Cancer Prev; 2022 Feb; 23(2):591-599. PubMed ID: 35225472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Circulating prostate cells and bone marrow micro-metastasis and not treatment modality determine the risk and time to biochemical failure in low risk prostate cancer.].
    Murray NP; Aedo S; Fuentealba C; Salazar A; Reyes E; Lopez MA; Minzer S
    Arch Esp Urol; 2019 Dec; 72(10):1000-1009. PubMed ID: 31823848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Circulating prostate cells and bone marrow micrometastasis are determinant in risk and time to biochemical progression in localized prostate cancer.].
    Murray NP; Aedo S; Fuentealba C; Reyes E; Minzer S; Salazar A
    Arch Esp Urol; 2019 Jun; 72(5):471-482. PubMed ID: 31223125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimal Residual Disease Defines the Risk and Time to Biochemical Failure in Patients with Pt2 and Pt3a Prostate Cancer Treated With Radical Prostatectomy: An Observational Prospective Study.
    Murray NP; Aedo S; Fuentealba C; Reyes E; Salazar A; Lopez MA; Minzer S; Orrego S; Guzman E
    Urol J; 2020 May; 17(3):262-270. PubMed ID: 31912475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Possible Role of Matrix Metalloprotienase-2 in the Relapse in Patients with Stage II Colon Cancer Treated by Curative Surgery.
    Murray NP; Villalon R; Aedo S; Hartmann D; Rodriguez MP
    Asian Pac J Cancer Prev; 2023 Oct; 24(10):3373-3379. PubMed ID: 37898840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The CAPRA-S score versus subtypes of minimal residual disease to predict biochemical failure after radical prostatectomy.
    Murray NP; Aedo S; Fuentealba C; Reyes E; Salazar A; Guzman E; Orrego S
    Ecancermedicalscience; 2020; 14():1063. PubMed ID: 32728379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of laparoscopic resection of colorectal carcinoma from the viewpoint of molecular biology.
    Skrovina M; Duda M; Srovnal J; Bartos J; Radova L; Hajduch M; Soumarova R
    Wideochir Inne Tech Maloinwazyjne; 2012 Mar; 7(1):19-26. PubMed ID: 23255996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minimum Residual Disease in Patients Post Radical Prostatectomy for Prostate Cancer: Theoretical Considerations, Clinical Implications and Treatment Outcome.
    Murray NP; Aedo S; Fuentealba C; Reyes E; Salazar A
    Asian Pac J Cancer Prev; 2018 Jan; 19(1):229-236. PubMed ID: 29374406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Epstein criteria predict for organ-confined prostate cancer but not for minimal residual disease and outcome after radical prostatectomy.
    Murray NP; Fuentealba C; Reyes E; Salazar A; Guzman E; Orrego S
    Turk J Urol; 2020 Sep; 46(5):360-366. PubMed ID: 32707032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years.
    Kolstad A; Pedersen LB; Eskelund CW; Husby S; Grønbæk K; Jerkeman M; Laurell A; Räty R; Elonen E; Andersen NS; Brown PD; Kimby E; Bentzen H; Sundström C; Ehinger M; Karjalainen-Lindsberg ML; Delabie J; Ralfkiær E; Fagerli UM; Nilsson-Ehle H; Lauritzsen GF; Kuittinen O; Niemann C; Geisler CH;
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):428-435. PubMed ID: 28039078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of circulating tumor cells in evaluation of prognosis and treatment response in advanced non-small-cell lung cancer.
    Zhou J; Dong F; Cui F; Xu R; Tang X
    Cancer Chemother Pharmacol; 2017 Apr; 79(4):825-833. PubMed ID: 28289866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytokeratin-19 mRNA-positive circulating tumor cells during follow-up of patients with operable breast cancer: prognostic relevance for late relapse.
    Saloustros E; Perraki M; Apostolaki S; Kallergi G; Xyrafas A; Kalbakis K; Agelaki S; Kalykaki A; Georgoulias V; Mavroudis D
    Breast Cancer Res; 2011 Jun; 13(3):R60. PubMed ID: 21663668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring with circulating tumor cells in the perioperative setting of patients with surgically treated stages I-IIIA NSCLC.
    Garitaonaindia Y; Aguado-Noya R; Garcia-Grande A; Cordoba M; Coronado Albi MJ; Campo Cañaveral JL; Calvo V; Clemente MB; Álvarez R; Peñas M; Chara L; Royuela A; Provencio M
    Transl Lung Cancer Res; 2023 Jul; 12(7):1414-1424. PubMed ID: 37577300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.